Rep. Marjorie Taylor Greene Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Representative Marjorie Taylor Greene disclosed her purchase of shares in Novo Nordisk A/S (NYSE:NVO), acquiring between $1,001 and $15,000 on October 15th.
• Novo Nordisk A/S recently reported a quarterly earnings per share of $0.97, exceeding estimates, and achieved a market cap of $238.29 billion.
• Several analysts upgraded Novo Nordisk A/S ratings, with a consensus price target of $76.00, indicating strong market interest and potential for growth.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on October 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on October 15th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 10/15/2025.
• Purchased $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 10/15/2025.
• Purchased $1,001 - $15,000 in shares of Exelon NASDAQ: EXC on 10/15/2025.
• Purchased $1,001 - $15,000 in shares of iShares Bitcoin Trust ETF NASDAQ: IBIT on 10/15/2025.
• Purchased $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 10/15/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 10/9/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 10/9/2025.
• Purchased $1,001 - $15,000 in shares of iShares Bitcoin Trust ETF NASDAQ: IBIT on 10/9/2025.
• Purchased $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 9/11/2025.
• Purchased $1,001 - $15,000 in shares of iShares Bitcoin Trust ETF NASDAQ: IBIT on 9/11/2025.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $53.37 on Thursday. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $116.43. The firm's 50-day simple moving average is $56.51 and its two-hundred day simple moving average is $62.52. The firm has a market cap of $238.29 billion, a price-to-earnings ratio of 14.66, a P/E/G ratio of 2.49 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's payout ratio is 22.53%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a research report on Wednesday, August 13th. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Rothschild Redb raised Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Finally, Morgan Stanley lowered Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and dropped their price objective for the company from $59.00 to $47.00 in a research note on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $76.00.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in shares of Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company's stock worth $1,303,466,000 after purchasing an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company's stock worth $867,998,000 after purchasing an additional 187,789 shares during the last quarter. Kingstone Capital Partners Texas LLC raised its holdings in shares of Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock valued at $690,560,000 after purchasing an additional 10,001,898 shares in the last quarter. Folketrygdfondet raised its stake in Novo Nordisk A/S by 6.9% in the first quarter. Folketrygdfondet now owns 9,521,912 shares of the company's stock worth $661,202,000 after buying an additional 617,974 shares in the last quarter. Finally, Sustainable Growth Advisers LP lifted its holdings in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company's stock worth $427,416,000 after buying an additional 649,390 shares during the period. Institutional investors own 11.54% of the company's stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.